🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2024-516415-24-03
Authorised Phase IV

Rapid sequence emergence of general Anaesthesia

2024-516415-24-03 · tracked via the Priya Life Science EU tracker
Sponsor
Stichting Radboud universitair medisch centrum
Sponsor type
Hospital/Clinic/Other health care facility
Therapeutic area
Anesthesia and Analgesia
Decision date
02/12/2025
Enrollment target
10
Sites
Netherlands

Condition studied

General anesthesia

Investigational medicinal product(s)

Sugammadex hameln 100 mg/ml oplossing voor injectieNaloxon HCl Accord 04 mg/mloplossing voor injectie / infusie in een voorgevulde spuitANEXATE 05 mg/5 mlsolution injectable (I.V.)REMIMAZOLAMSufentanil Viatris 5 microgram/ml oplossing voor injectieEsmeron 10 mg/mloplossing voor injectie

Eligibility

Age group
18-64 years
Sex
Female, Male

Primary endpoint

Time to the return of spontaneous breathing

Endpoint detail

Time to opening the eyes, Time to return of airway reflexes (swallow-ing, coughing), Respiratory effects (saturation, respiratory rate, capnography), Hemodynamic effects (blood pressure, heart rate), Bispectral Index Score (BIS), Neuromuscular block depth, Physician satisfaction, Total time to emerge from anaesthesia (to-tally awake, as before induction)

Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2024-516415-24-03 on CTIS ↗ ← All trials in the EU